A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
about
Vitamin C and Vitamin E for Alzheimer's DiseaseThe cholinergic hypothesis of Alzheimer's disease: a review of progressCurrent pharmacologic options for patients with Alzheimer's diseaseEfficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialRecommendations for the management of behavioral and psychological symptoms of dementia.Meta-analysis of continuous outcome data from individual patients.Donepezil: a clinical review of current and emerging indications.Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease.Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.Defining meaningful change in Alzheimer's disease trials: the donepezil experience.Management of neurological disorders: dementia.Acetylcholinesterase inhibitors in Alzheimer's disease.North of England evidence based guidelines development project: guideline for the primary care management of dementiaNew drug treatment for Alzheimer's disease. Doctors want to offer more than sympathy.Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.Neurotransmitter replacement therapy in Alzheimer's disease.Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease.Detecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessmentMild cognitive impairment: emerging therapeutics.Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status.Drugs for dementia: the first year. An audit of prescribing practice.Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.Treatment of dementia with neurotransmission modulation.The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomesClinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014The safety and tolerability of donepezil in patients with Alzheimer's disease.Donepezil use in Alzheimer disease.Tacrine: first drug approved for Alzheimer's disease.Copy number variants in pharmacogenetic genes.Aqueous Extract of Black Maca (Lepidium meyenii) on Memory Impairment Induced by Ovariectomy in Mice.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Long-term cholinesterase inhibitor therapy for Alzheimer's disease: implications for long-term care.A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease.Therapeutic approaches to age-associated neurocognitive disordersCholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.Pharmacotherapy of dementia with Lewy bodies.Differences between clinical trials and postmarketing use.Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease.
P2860
Q22241556-EFD7219F-FC96-43BA-88C1-35EA8B0C8E9DQ22242019-0701C624-C2DA-4E24-AE5A-31B79C3E4795Q24800530-0AFE1285-F7B1-4E5B-9BE3-5162FC1F59C8Q28343193-15D9DCB5-74B9-425B-A609-A77146C54454Q30327961-CE8A3D22-0D02-4E27-A469-70E39E507D4CQ30657054-0CB7E9D6-B329-4447-916B-73887BFB904DQ33150809-929E659E-726F-47F2-8732-5270BCD5BBC9Q33637687-67F3670E-F079-42EB-BAD1-72C7AA9DD56EQ33662063-6EFB9E24-D3DA-4AEF-87B3-E1D7B23084B7Q33662471-4DD365BF-9229-423C-9E7C-EDA3C5ACF676Q33711100-6189F745-E56B-49E3-BA5D-601C490EA008Q33733383-D9DD8935-EBF1-42C3-BF4D-EE5E1C03F8B7Q33785568-41526282-C0F7-46C6-90A7-D7B80ECD0F3DQ33791951-B938CADF-4594-4748-AEEF-F8B9C819FB04Q33792081-186E527B-F377-4239-A085-614E5FDF6B66Q33830572-931F48AF-E7CA-4402-BDFD-F2E19B23E172Q33921314-E45BD07C-AA9C-4BBA-A507-206B51826D74Q33921804-2B17D8DA-87E0-4809-A64B-9E20CAD8C8C0Q33938233-AB65B4B5-9C70-41A3-8C39-90945E9413ECQ34052739-67FA8E99-11A4-477B-97EB-8D9D1DCDDFC1Q34072149-DC76C4F2-62B8-4DEE-A7D6-DED8ED72E1F1Q34119518-92794A3F-0D34-42DE-AF11-A048A7949786Q34150502-DE765D32-408B-4BFE-B73B-DD8FF2D37FB2Q34240980-A72EE58B-ECA8-4473-8C14-6C6F04DD67BCQ34266258-050F7ED7-9FB9-485E-8166-DF650A25A4E0Q34346464-8CC35943-1376-404E-82E6-5A08E5AE4632Q34408888-EFEA1918-620B-4C8D-B8A7-D455B49C6D86Q34552035-D033301F-046B-4D7B-9CE3-9BA41B1DFAD6Q34663361-2C004914-6B9A-490C-8691-4AF8949078B2Q34724675-B398652F-CB57-4ACD-8CE2-0EEE1959523AQ34975631-2FEE8F0F-CC78-4BDF-822B-BFF39C1DFFDEQ34986959-2CC76EBA-5D41-4A9A-90A4-3B7CC153F232Q35015993-A5EB8C51-F33B-46B0-B804-CA6A55D935A0Q35112092-A5559895-6CCD-4166-9F03-F88D47DF29EBQ35236228-83378035-CA7E-46B4-A070-353F170F96E5Q35236387-68B911ED-71E2-4B26-A2EA-B20073298FA8Q35465836-DE45E8BF-F25A-4452-B334-F899ECA488E8Q35574995-A09693D4-3DD3-487E-B84F-DE39CB309AD7Q35825899-4A068CF1-CCE4-4E87-954B-BD87C8B62562Q35998803-231C6327-ED04-4102-9F1A-370F3C72F1E9
P2860
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
@en
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
@nl
type
label
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
@en
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
@nl
prefLabel
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
@en
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
@nl
P2093
P1476
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
@en
P2093
C H Sadowsky
J Dolan-Ureno
L A Hershey
S I Gracon
P304
P356
10.1001/JAMA.1992.03490180055026
P407
P577
1992-11-01T00:00:00Z